Desentum Oy:n varsinainen yhtiökokous pidetään 22.6.2022 / The AGM of Desentum Oy is to be held on Jun 22nd, 2022.Read more »
Below you can find the latest news releases from Desentum.
Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros in a funding round arranged by Springvest Oyj. Desentum intends to use the proceeds for funding...Read more »
Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker results indicated a favourable immunological response.Read more »
Desentum Oy:n varsinainen yhtiökokous pidetään 25.5.2021 / The AGM of Desentum Oy is to be held on May 25th, 2021.Read more »
Dosing has been completed for all study subjects in Desentum’s First-in-Human clinical study of DM-101, a novel allergy vaccine intended for treating birch pollen allergy. Last follow-up visits will be completed during Q2/2021 and study results are expected in Q3/2021.Read more »